BRIVANT LIMITED

Their core work

BRIVANT LIMITED, operating under the brand Integer in Galway, Ireland, is an industrial medical device company specialising in catheter-based systems used in cardiac intervention procedures. Their H2020 work centres on smart catheters — including IVUS (intravascular ultrasound), FFR (fractional flow reserve), and ICE (intracardiac echocardiography) devices — developed within open platform architectures that allow cath lab equipment to interoperate. They also contribute manufacturing and technology expertise to initiatives accelerating microfabrication of next-generation implantable medical devices. Their role in EU research is consistently that of an industrial participant bringing production-scale perspective to pilot line and enabling platform consortia.

What they specialise in

How they've shifted over time

In their initial H2020 engagement (POSITION-II, 2018), Integer's focus was highly specific — catheter-based cardiology tools (IVUS, FFR, ICE) and implantables, with the concrete goal of establishing a pilot manufacturing line for named device types. By 2020 (Moore4Medical), the vocabulary shifted away from device-specific terms toward "open and enabling technology platforms", reflecting a broader interest in the fabrication infrastructure that underpins next-generation medical devices rather than individual product categories. The trajectory suggests Integer is moving from device-specific expertise toward platform and manufacturing technology roles within the wider medtech ecosystem.

Integer appears to be broadening from catheter-specific innovation toward platform-level medical device manufacturing, making them potentially valuable for any consortium needing an industrial partner who understands both device requirements and scalable microfabrication.

How they like to work

Integer consistently joins as a participant rather than taking on coordination responsibilities, indicating they prefer to contribute focused technical or manufacturing expertise within larger, externally-led initiatives. Their 90 unique partners across just two projects signals involvement in very large, diverse Innovation Action consortia — typical of EU pilot line programmes where many industrial and academic players combine. This profile is consistent with a company that adds production credibility and scale-up know-how rather than driving the research agenda.

Integer has connected with 90 unique partners across 14 countries through just two projects, reflecting the large consortium structures common to EU pilot line and platform Innovation Actions. Their network almost certainly spans research institutes, SMEs, and large industrial firms across Western Europe typical of medical device programmes under the ICT pillar.

What sets them apart

Integer is one of the few private industrial companies based in Ireland's medtech corridor (Galway) contributing to EU-funded catheter and implant pilot lines — a segment otherwise dominated by research institutes and university spin-outs. Their combination of cath lab device knowledge (IVUS, FFR, ICE) and engagement with open platform frameworks places them at the intersection of device manufacturing and digital medical ecosystems, which is unusual for a single industrial partner. For consortia building Innovation Actions in interventional cardiology or microfabricated devices, Integer brings the industrial production perspective that academic and startup partners typically cannot provide.

Highlights from their portfolio

• POSITION-II
  A large Innovation Action establishing a physical pilot manufacturing line for smart catheters and implants — one of the most capital-intensive device categories in interventional cardiology, with Integer receiving EUR 117,500 as a participant.
• Moore4Medical
  A platform-level initiative targeting microfabrication across multiple medical device types, signalling Integer's deliberate move beyond catheter-specific work toward broader enabling technology and manufacturing platform roles.